Worse PFS Seen with Nivolumab-Rucaparib in Ovarian Cancer
The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly
The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly
The food system in Asia is facing a triple food safety threat in the firm of microbiological, chemical and physical
“You look at us coming in and being on the bubble - 21 points out with a ton of pressure
No posts found.